ST. LOUIS–(BUSINESS WIRE)–C2N Diagnostics, LLC (“C2N”) announces it has received its laboratory permit from the highly respected New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP). This accomplishment allows C2N to offer its PrecivityAD2™ and PrecivityAD® blood tests to help diagnose Alzheimer’s disease in New York State. The Empire State joins 49 other states, Washington, D.C., Puerto Rico and select countries across Asia, Latin America, Europe and the Middle